Ebun Garner sold $671k of ERAS
General Counsel & Corp. Sec. at Erasca, Inc.. 120,000 shares at an average of $5.59, traded Jan 7, 2026, filed Jan 8, 2026.
Score components
- +15RoleOfficer
- +20Trade size$671k at market
- +20Share of holdings soldSold 83% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +111.5%, 3m +198.8%, 6m +230.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-008076, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 15, 2025 | AGrant or award Common Stock10b5-1 | +3,902 | $1.19 | $4,660 | 25,076 | Jan 8, 2026 |
| Jan 7, 2026 | MOption exercise Common Stock10b5-1 | +120,000 | $1.70 | $204k | 145,076 | Jan 8, 2026 |
| Jan 7, 2026 | SOpen-market sale Common Stock10b5-1 | -120,000 | $5.59 | $671k | 25,076 | Jan 8, 2026 |
| Jan 7, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -120,000 | $0.00 | $0 | 360,000 | Jan 8, 2026 |
Related signals
Other insiders at Erasca, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | Erasca, Inc. | Ebun Garner Chief Legal Officer | $1.3M 80,000 shares | -76% | |
| 14Weak | Erasca, Inc. | Shannon Morris Chief Medical Officer | $301k 20,000 shares | -100% | |
| 58Moderate | Erasca, Inc. | Valerie Denise Harding Start director | $18k 10,000 shares | +100% | |
| 86Strong | Erasca, Inc. | Jonathan E Lim Chairman & CEO | $1.7M 1,000,000 shares | +8% | |
| 58Moderate | Erasca, Inc. | Alexander W. Casdin director | $50k 30,000 shares | +6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.